A completely valid question. Sales of Mabthera have continued to grow, but it is not possible to find any break-out of sub sales.
One can, and will, only conjecture on the significance of this based on ones point of view. Observer bias. Mabthera is a big seller. I'd like to know why sun isn't being more visibly touted.
Janssen's new myeloma drug received unusually rapid FDA approval. Bodes well for the HALO partner, perhaps. That's only if the FDA doesn't totally freak about the antibodies. Oh, goodness, the antibodies!
Yes. If all the cheerleaders on this board have held the stock as long as I have, then we're all losing money. Earnings a welcome development, but it's too soon to get excited. At least this should keep tax loss selling to a minimum.
What I find really intriguing is this. Baxter did the heavy lifting on background of biologic activity for the Hyquvia approval. All that science won't have to be repeated. Once the partner drugs are approved , getting approval for this dosing method should have few or no hurdles. It's only a matter of establishing non-inferiority of the subq vs intravenous delivery. We could see a subq Humira relatively quickly. And the Janssen will certainly get approved based on their recent demonstration of efficacy. It could come out of the gate as a subq formula. It's going to be an interesting cc.
Really consistent performance here for several quarters. Price action today was disappointing, though. Would have loved to see them tweek the revenue guidance up a bit.
HALO volume remains tepid. I think the blockbuster potential of Humira on Halozyme revenues and validation of the platform has still not been factored into the stock price.
Lots of enthusiasm on this board, but this is the third conference call talking up of "tier one" costumers, but still no volume product in the market or clear indication of when there will be one. Still just talk.
Great post. Reading this and considering the potential of the PEGh20 platform on top of it, makes mw wonder if $27 price target isn't pretty conservative? But then , here we are at $15. I know we're all hoping to find that a 50% price correction was an extraordinary opportunity.
Nice post. HALO needs to make it's numbers ex-one time payments, meaning product revenue, and we might get some mojo back. I'd like to see some improved uptake for herceptin SQ. I think the numbers last time were tepid,and coincided with the beginning of this price decline. Whether that's causal or not, who knows. Definitely need to get the diagnostic into the mix to move ahead with phase 3. This kind of commentary is certainly encouraging.
The PT was raised to $28 in June. Have they updated their analysis?